Mammalian immune cells

Mammalian immune cells, collectively known as leukocytes, are the primary cellular components of the immune system responsible for protecting the host from pathogenic infections and maintaining tissue homeostasis (Janeway et al., Immunobiology, 2001). This broad category includes innate immune cells like macrophages, neutrophils, and natural killer cells, as well as adaptive immune cells such as B and T lymphocytes (NIH, National Institute of Allergy and Infectious Diseases). While 'mammalian immune cells' is a biological system rather than a specific molecular target, these cells express a vast array of receptors, enzymes, and ion channels that serve as the actual therapeutic targets for drug intervention. In oncology, drugs like checkpoint inhibitors are used to reactivate T-cell responses against tumors, while in autoimmune diseases, immunosuppressants are used to dampen the overactive response of these cells (Nature Reviews Drug Discovery, 2018). Therapeutic modulation of these populations is a cornerstone of modern medicine, though it carries significant risks such as systemic immunosuppression or life-threatening cytokine storms (StatPearls, 2023). Because this term refers to a heterogeneous population of cells rather than a single protein or molecule, it is considered too broad to be a specific therapeutic target in a molecular context.

Other names

LeukocytesWhite blood cellsImmune system cellsHematopoietic immune cells

Drugs do not target mammalian immune cells as a single entity; instead, they interact with specific molecular components such as surface receptors (e.g., PD-1, CD20), cytokines (e.g., TNF-alpha), or intracellular signaling enzymes (e.g., JAK kinases) to modulate cell activity, induce depletion, or suppress inflammatory signaling (Nature Reviews Drug Discovery, 2018; PubChem).